Breadcrumb navigation

NEC and Transgene to present recent developments from TG4050 at the American Association of Cancer Research Conference

Tokyo, Japan; March 15, 2023 NEC Corporation today announced its participation in the American Association of Cancer Research (AACR) Annual meeting which will take place in Florida, USA, from April 14–19, 2023. TG4050 is a personalized cancer vaccine that uses NEC's cutting-edge AI-based Neoantigen Prediction System and Transgene’s innovative virus engineering platform myvac®.


Title: Feasibility and immunogenicity of adjuvant TG4050, a patient tailored cancer vaccine in head and neck and ovarian cancer

  • Session title: Late-Breaking Research: Clinical Research 2
  • Poster and abstract number: LB205
  • Date and Time: Tuesday April 18, 2023; 9:00 AM - 12:30 PM ET
  • Location: Board 20, Section 35
  • Authors: Ana Lalanne, Camille Jamet, Christian H. Ottensmeier, Jean-Pierre Delord, Christophe Le Tourneau, Matthew S. Block, Gerardo Colon-Otero, Keith L. Knutson, Annette Tavernaro, Gisele Lacoste, Benoit Grellier, Xavier Noiriel, Thierry Huss, Bernard Burtin, Yoshiko Yamashita, Kousuke Onoue, Kazuhide Onoguchi, Brandon Malone, Olivier Lantz, Oliver Baker, Naoko Yamagata, Yuki Tanaka, Eric Quemeneur, Maud Brandely, Kaidre Bendjama

About the clinical trials
TG4050 is being evaluated in two Phase I clinical trials for patients with ovarian cancer (new windowNCT03839524) and HPV-negative head and neck cancers (new windowNCT04183166). 

About TG4050
TG4050 is an individualized immunotherapy being developed for solid tumors that is based on Transgene’s myvac® technology and powered by NEC’s longstanding artificial intelligence (AI) expertise. This virus-based therapeutic vaccine encodes neoantigens (patient-specific mutations) identified and selected by NEC’s Neoantigen Prediction System. The prediction system is based on more than two decades of expertise in AI and has been trained on proprietary data allowing it to accurately prioritize and select the most immunogenic sequences.
TG4050 is designed to stimulate the immune system of patients in order to induce a T-cell response that is able to recognize and destroy tumor cells based on their own neoantigens. This individualized immunotherapy is developed and produced for each patient.

About NEC’s Neoantigen Prediction System
NEC's neoantigen prediction system utilizes its proprietary AI, such as graph-based relational learning, trained on multiple sources of biological data to discover candidate neoantigen targets. These targets are carefully analyzed using proprietary machine learning algorithms that include in-house HLA binding and antigen presentation AI tools to evaluate the likelihood of eliciting a robust and clinically relevant T cell response. With NEC OncoImmunity now onboard, NEC continues to strengthen its top class neoantigen prediction pipelines with the aim of maximizing the therapeutic benefits of personalized cancer immunotherapy for patients worldwide. For more information, visit NEC at For additional information, please also visit NEC OncoImmunity at new window 

About Transgene
Transgene (Euronext: TNG) is a biotechnology company focused on designing and developing targeted immunotherapies for the treatment of cancer. Transgene’s programs utilize viral vector technology with the goal of indirectly or directly killing cancer cells.
The Company’s clinical-stage programs consist of two therapeutic vaccines (TG4001 for the treatment of HPV-positive cancers, and TG4050, the first individualized therapeutic vaccine based on the myvac® platform) as well as three oncolytic viruses based on the Invir.IO™ viral backbone (TG6002, BT-001 and TG6050).
With Transgene’s myvac® platform, therapeutic vaccination enters the field of precision medicine with a novel immunotherapy that is fully tailored to each individual. The myvac® approach allows the generation of a virus-based immunotherapy that encodes patient-specific mutations identified and selected by Artificial Intelligence capabilities provided by its partner NEC.
With its proprietary platform Invir.IO™, Transgene is building on its viral vector engineering expertise to design a new generation of multifunctional oncolytic viruses. Transgene has an ongoing Invir.IO™ collaboration with AstraZeneca.
Additional information about Transgene is available at: Twitter: new window@TransgeneSA– LinkedIn: new window@Transgene
Follow us on social media:

Links: TO new windowAACR WEBSITE only (ABSTRACT only available after April 14)

For more information
NEC's Drug Discovery Business
new window